Why Is Cancer Therapy Such a Difficult and Often Intractable Effort?

Slides:

Advertisements

Similar presentations

Lessons from Hereditary Colorectal Cancer

Advertisements

VogelsteinScience15Apr13.ppt Updated: April 15, 2013 Why Is Cancer Therapy Such a Difficult and Often Intractable Effort? Cancer Genome Landscapes. Science,

Is phosphorylation site disruption associated with cancer? Maricel G. Kann (University of Maryland, Baltimore County) Matthew E. Mort (Indiana University.

Cancer &Oncogenes. Objectives Define the terms oncogene, proto-oncogenes and growth factors giving examples. Describe the mechanisms of activations of.

Cancer Genome Landscapes

Tyrosine Kinases as Targets for Cancer Therapy Krause DS, Van Etten RA N Engl J Med 2005;353(2): Krause DS, Van Etten RA N Engl J Med 2005;353(2):

CAP Cancer BioMarker Reporting Committee Biomarker - Problem, ROI and Scope College of American Pathologists’ Biomarker Reporting Committee Problem 1.Clinicians.

Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing by Rebecca J. Leary, Isaac Kinde, Frank Diehl, Kerstin Schmidt, Chris.

Big Data in Genomics, Diagnostics, and Precision Medicine

Samsung Genome Institute Samsung Medical Center

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.

Model for regulation of the Ras p21 product and for the GTPase-activating protein (GAP) as a downstream effector and regulator of ras activity. Ras is.

Combinatorial interactions of cyclins and cyclin-dependent kinases (cdks) during the cell cycle. Progression from G0 through the restriction point in G1.

The Department of Biochemistry & Molecular Biology

Molecular Dissection of Complete Response to Receptor Tyrosine Kinase Inhibition in Type II Papillary Renal Cell Carcinoma Matti Annala, Lucia Nappi,

Gatekeeper, caretaker, and landscaper mutations

FREQUENCIES of altered genes RECURRENT variants & mutated genes

Targeting signal transduction

Kicking Genomic Profiling to the Curb: How Re-wiring the Phosphoproteome Can Explain Treatment Resistance in Glioma Fred C. Lam, Michael B. Yaffe Cancer.

A Paradigm Shift From One-Size-Fits-All to Tailor-Made Therapy for Metastatic Colorectal Cancer.

Ira J. Blader, PhD Microbial Infection and Immunity Seminar Series

Inhibitor of MAP kinase activation blocks colon cancer growth

Genetics of Cancer.

BRAF inhibitor: targeted therapy in hairy cell leukemia

Chapter 17: Regulation of cell number

Figure 1 Current treatments for PNETs

Figure 4 Possible combination therapies CDK4/6 inhibitors

Dan Gordon Gastroenterology Volume 114, Issue 4, (April 1998)

Extracellular Regulation of Apoptosis

Cancer Genomics: The Road Ahead

Immunotherapy: The Path to Win the War on Cancer?

Nat. Rev. Urol. doi: /nrurol

Fig. 1 Number of somatic mutations in representative human cancers, detected by genome-wide sequencing studies. Number of somatic mutations in representative.

Mutational burden of somatic, protein-altering mutations per subject from WES for patients with advanced colon cancer who participated in PD-1 blockade.

Why Is Cancer Therapy Such a Difficult and Often Intractable Effort?

Let to development of a class of antibodies (organic molecules) that are known as immune checkpoint inhibitors which are now used for cancer therapies.

A genome-based strategy uncovers frequent BRAF mutations in melanoma

Toru Furukawa Clinical Gastroenterology and Hepatology

A. Craig Lockhart, Mace L. Rothenberg, Jordan D. Berlin

Emerging Themes in Biology: Hints for the Future

Nat. Rev. Urol. doi: /nrurol

Vascular Endothelial Growth Factor (VEGF) Pathway

Characterizing the Killer Colorectal Carcinomas

The Antisense Transcriptomes of Human Cells

Detection rate for EGFR mutations in cfDNA.

Retrospective Multicenter Study Investigating the Role of Targeted Next-Generation Sequencing of Selected Cancer Genes in Mucinous Adenocarcinoma of the.

Nat. Rev. Nephrol. doi: /nrneph

Mona Malz, Federico Pinna, Peter Schirmacher, Kai Breuhahn

The RAF Inhibitor Paradox Revisited

Clinical courses of patients.

Overview of the complex interactions among molecular classifications of TNBC based on genomic, transcriptomic, proteomic, epigenomic, and immune characterization.

Genetic landscape of salivary duct carcinoma.

(A) Survival time. (A) Survival time. All patients. (a) PFS since the start of EGFR-TKI (groups A, B and C). (b) OS since the start of EGFR-TKI (groups.

RAS and PD-L1: A Masters’ Liaison in Cancer Immune Evasion

Contributions of Insulin-Resistance and Insulin-Secretory Defects to the Pathogenesis of Type 2 Diabetes Mellitus John E. Gerich, MD Mayo Clinic Proceedings

Malignant Glioma: Lessons from Genomics, Mouse Models, and Stem Cells

LEQ: Why is the eukaryotic cell cycle regulated?

KJ Perspective Cell Signaling Lipids link ion channels and cancer Science 21 August 2015: Vol. 349 no pp Perspective Cell Signaling.

Progress in Cutaneous Cancer Research1

Molecular Characterization of Acquired Resistance to the BRAF Inhibitor Dabrafenib in a Patient with BRAF-Mutant Non–Small-Cell Lung Cancer Charles M.

Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.

The new kid on the block(ade) of the IGF-1 receptor

Mutant BRAF Melanomas—Dependence and Resistance

Detection and localization of surgically resectable cancers with a multi-analyte blood test by Joshua D. Cohen, Lu Li, Yuxuan Wang, Christopher Thoburn,

Personalized genomic analyses for cancer mutation discovery and interpretation by Siân Jones, Valsamo Anagnostou, Karli Lytle, Sonya Parpart-Li, Monica.

The treatment history and genomic landscape of a metastatic carcinoma with an extreme outlier response to combination therapy. The treatment history and.

Simplified BRAF signaling network.

Location of the ER mutations and frequencies per cohort.

Fig. 1 Number of somatic mutations in representative human cancers, detected by genome-wide sequencing studies. Number of somatic mutations in representative.

Presentation transcript:

Why Is Cancer Therapy Such a Difficult and Often Intractable Effort? Cancer Genome Landscapes. Science, Vol. 339, March 29, 2013, pp 1546 – 1548 Bert Vogelstein, Nickolas Papadopoulos, Victor Velculescu, Shibin Zhou, Luis Diaz, Kenneth W. Kinzler Howard Hughes Medical Institute at Johns Hopkins Kimmel Cancer Center, Baltimore VogelsteinScience15Apr13.ppt Updated: April 15, 2013

Number of somatic mutations associated with cancers in patients

From 5 or 10 to 130 to 700 mutations per tumor

(Insertions & deletions) (Single base substitutions)

Signaling Pathways Affected In Cancers

Pathway Anomalies in Progression in Colo-Rectal Cancer

The RAS Pathway as a representative signaling pathway affected by cancer mutations and approaches to therapy based on RAS pathway anomalies RTK = receptor tyrosine kinase